Dyadic International: Company Overview, Key Executives, and Recent News
Overview
Dyadic International, Inc. (DYAI) is a biotechnology company focused on developing and commercializing C1-immobilized enzymes and other proteins for the biopharmaceutical and industrial biotechnology industries.
The company's proprietary C1 technology platform enables the efficient large-scale manufacture of proteins, including enzymes, antibodies, and other therapeutic proteins.
Key Executives
- Patrick Lucy, Board Chairman
- Joe Hazelton, Chief Operating Officer
Recent News
On March 31, 2024, Dyadic International reported a revenue of $334.62 million for the quarter ending March 31, 2024, a decrease of 30.3% compared to the same period in 2023.
The company also announced that it had entered into an agreement with a leading pharmaceutical company to receive a total payment of $15 million for the development and commercialization of a novel enzyme.
Additional Information
- Website: https://www.dyadic.com/
- Headquarters: Jupiter, Florida
- Founded: 1997
- Ticker Symbol: DYAI
For more information on Dyadic International, please visit their website or consult other reputable sources.
Comments